Breckenridge Pharmaceutical, Inc. is voluntarily recalling to the consumer level one lot of Propranolol Hydrochloride Extended-Release Capsules, USP, 60 mg, manufactured by Adare Pharma Solutions, due to potential metal contamination, according to a company announcement dated Nov. 16 and posted by the Food and Drug Administration on Nov. 20. The FDA published the announcement as a public service and does not endorse the product or the company.
Use of product from the affected lot "could potentially cause lacerations of soft tissues in the oral cavity, esophagus, stomach, or intestine," the company said. The affected lot shared intermediate material suspected to be the source of metal contamination identified in a separate lot that was not released to market. To date, Breckenridge is not aware of any adverse events assessed to be related to this recall. Product from the affected lot was distributed nationwide to wholesalers and pharmacies between Oct. 26, 2026, and Nov. 4, 2026, the announcement said.
The recalled product is Propranolol Hydrochloride Extended-Release Capsules, USP, 60 mg, in a 100-count bottle, NDC 51991-817-01, lot number PK25110035, with an expiration date of May 2029, branded as Breckenridge. Consumers should immediately stop taking product from that lot and contact their physician or healthcare provider for medical advice and replacement instructions, and should return any unused portion of the affected product to the pharmacy where it was obtained, the company said. Consumers should also contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this product.
Wholesalers, pharmacies, and other retail entities should check inventory for the recalled lot, quarantine any affected product, and not distribute or dispense it. Entities that further distributed the product should notify their sub-accounts to the retail level, the announcement said. For questions, the company directed people to Qualanex, its designated recall service provider, Monday through Friday, 9 a.m. to 5 p.m. Eastern Time, at 1-855-736-0807 or [email protected]. Adverse reactions or quality problems may be reported to the FDA's MedWatch program. The company said the recall is being conducted with the knowledge of the FDA. This story describes a single-lot consumer-level recall of the 60 mg extended-release capsules identified above, not a recall of all propranolol products or other strengths, and it is not medical advice.
The company announcement is dated Nov. 16, 2026; the FDA publish date on the posted page is Nov. 20, 2026. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program online at fda.gov/medwatch/report.htm, or by mail or fax using a form requested at 1-800-332-1088 or downloaded from fda.gov/MedWatch/getforms.htm, with completed forms faxed to 1-800-FDA-0178, the announcement said. Media inquiries were directed to Towa International / Breckenridge Pharmaceutical's external communications and investor-relations team at [email protected]. Consumers with recall questions should use the Qualanex contacts above rather than stopping a prescribed beta blocker without talking to a clinician, which is the company's stated instruction to seek medical advice and replacement instructions.
